{"entity":{"id":"nct06652412","kind":"trial","name":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC","aka":[],"tldr":"A phase 2 trial of sintilimab, fluorouracil (5-FU), raltitrexed, fOLFOX (5-FU, leucovorin, oxaliplatin) and other drugs in colorectal cancer, run by Fudan University, not yet recruiting.","summary":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC is a phase 2, interventional study registered as NCT06652412 by Fudan University, with a registry enrolment figure of 124 participants, started 2024-11 and due to reach its primary completion in 2027-11. Interventions recorded: Ultrafractionated RT and CGA Guided systemic treatment.; data prospectively collected; Ultrafractionated Radiotherapy; Sintilimab; Fluorouracil; Raltitrexed; Oxaliplatin; Irinotecan (CPT-11). Conditions listed: Colon Cancer; Rectal Cancer. Primary outcome: Complete response (CR) rate. Colorectal eligibility wording from the registry: \"Pathologically confirmed Colorectal adenocarcinoma;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06652412","url":"https://clinicaltrials.gov/study/NCT06652412"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["sintilimab","fluorouracil","raltitrexed","folfox","folfiri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06652412","phase":"2","setting":"Comprehensive Geriatric Assessment (CGA) Guided Ultrafractionated Radiotherapy and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized Colorectal Cancer","sponsor":"Fudan University","enrolled":124,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06652412/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"raltitrexed","kind":"drug","name":"Raltitrexed","route":"/drugs/raltitrexed/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}